Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析

◆英語タイトル:Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1331
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,125見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,375見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ultragenyx Pharmaceutical Inc (RARE) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ultragenyx Pharmaceutical Inc (Ultragenyx) develops novel therapeutics for rare and ultra-rare genetic diseases. It has two marketed products, Mepsevii (vestronidase alfa) is approved for the treatment of adults and children with Mucopolysaccharidosis (MPS) VII (Sly syndrome) and Crysvita (burosumab), a fully human monoclonal antibody for the treatment of X-linked hypophosphatemia (XLH). Its pipeline includes Crysvita for the treatment of tumor-induced osteomalacia (TIO); DTX401 for the treatment of patients with glycogen storage disease type Ia, or GSDIa; UX007 for the treatment of LC-FAOD and DTX301 for the treatment of ornithine transcarbamylase. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.

Ultragenyx Pharmaceutical Inc Key Recent Developments

Apr 01,2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder
Mar 31,2020: Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing …
Mar 31,2020: Regenxbio teams up with Ultragenyx in gene therapy for rare metabolic disorder
Mar 31,2020: REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ultragenyx Pharmaceutical Inc – Key Facts
Ultragenyx Pharmaceutical Inc – Key Employees
Ultragenyx Pharmaceutical Inc – Key Employee Biographies
Ultragenyx Pharmaceutical Inc – Major Products and Services
Ultragenyx Pharmaceutical Inc – History
Ultragenyx Pharmaceutical Inc – Company Statement
Ultragenyx Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Ultragenyx Pharmaceutical Inc – Business Description
Product Category: Crysvita
Overview
Performance
Product Category: Mepsevii
Overview
Performance
Product Category: UX007
Overview
Performance
Geographical Segment: All other
Performance
Geographical Segment: Europe
Performance
Geographical Segment: US
Performance
R&D Overview
Ultragenyx Pharmaceutical Inc – Corporate Strategy
Ultragenyx Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
Ultragenyx Pharmaceutical Inc – Strengths
Ultragenyx Pharmaceutical Inc – Weaknesses
Ultragenyx Pharmaceutical Inc – Opportunities
Ultragenyx Pharmaceutical Inc – Threats
Ultragenyx Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 01, 2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder
Mar 03, 2020: Ultragenyx announces planned transition of Chief Financial Officer
Feb 13, 2020: Ultragenyx reports fourth quarter and full year 2019 financial results and corporate update
Jan 13, 2020: Ultragenyx reports preliminary 2019 revenue and provides 2020 Crysvita revenue guidance
Nov 05, 2019: Ultragenyx reports third quarter 2019 financial results and corporate update
Aug 01, 2019: Ultragenyx reports second quarter 2019 financial results and corporate update
Jun 17, 2019: Ultragenyx expands leadership team and promotes Erik Harris to chief commercial officer
May 06, 2019: Ultragenyx reports first quarter 2019 financial results and corporate update
Feb 19, 2019: Ultragenyx announces fourth quarter and full year 2018 financial results
Feb 04, 2019: Ultragenyx Pharmaceutical names Shehnaaz Suliman, M.D., to Board of Directors
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ultragenyx Pharmaceutical Inc, Key Facts
Ultragenyx Pharmaceutical Inc, Key Employees
Ultragenyx Pharmaceutical Inc, Key Employee Biographies
Ultragenyx Pharmaceutical Inc, Major Products and Services
Ultragenyx Pharmaceutical Inc, History
Ultragenyx Pharmaceutical Inc, Subsidiaries
Ultragenyx Pharmaceutical Inc, Key Competitors
Ultragenyx Pharmaceutical Inc, Ratios based on current share price
Ultragenyx Pharmaceutical Inc, Annual Ratios
Ultragenyx Pharmaceutical Inc, Annual Ratios (Cont...1)
Ultragenyx Pharmaceutical Inc, Interim Ratios
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Ultragenyx Pharmaceutical Inc, Performance Chart (2015 - 2019)
Ultragenyx Pharmaceutical Inc, Ratio Charts
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Entergy Corporation:企業の戦略・SWOT・財務情報
    Entergy Corporation - Strategy, SWOT and Corporate Finance Report Summary Entergy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Serodus ASA (SER)-製薬・医療分野:企業M&A・提携分析
    Summary Serodus ASA (Serodus) is a drug development company that focuses on the development of products for unmet medical needs in areas such as diabetes and diabetic comorbidities. The company’s pipeline products include SER150DN, an anti-inflammatory compound under development for diabetic nephrop …
  • Banque Cramer & Cie SA:企業の戦略・SWOT・財務情報
    Banque Cramer & Cie SA - Strategy, SWOT and Corporate Finance Report Summary Banque Cramer & Cie SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Lava Therapeutics BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Lava Therapeutics BV (Lava Therapeutics) is a biotechnology company which develops immune oncology biopharmaceuticals products. Its proprietary V?9Vd2 T-cell engager candidates bind to the conserved (monomorphic) T-cell receptor of V?9Vd2 T-cells which exhibit potent cytotoxicity, interferon …
  • CTI BioPharma Corp (CTIC):製薬・医療:M&Aディール及び事業提携情報
    Summary CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company’s lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or r …
  • Mitchells & Butlers plc:企業の戦略・SWOT・財務分析
    Mitchells & Butlers plc - Strategy, SWOT and Corporate Finance Report Summary Mitchells & Butlers plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • GS Yuasa Corporation (6674):企業の財務・戦略的SWOT分析
    GS Yuasa Corporation (6674) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • ABO Wind AG-エネルギー分野:企業M&A・提携分析
    Summary ABO Wind AG (ABO Wind) develops renewable energy projects in Europe. The company carries out the planning and environmental impact assessment, design, development, and operation of wind power projects and biomass power generating facilities. ABO Wind also provides long-term management or mai …
  • JALUX Inc:企業の戦略・SWOT・財務情報
    JALUX Inc - Strategy, SWOT and Corporate Finance Report Summary JALUX Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Family Dollar Stores, Inc.:企業の戦略・SWOT・財務情報
    Family Dollar Stores, Inc. - Strategy, SWOT and Corporate Finance Report Summary Family Dollar Stores, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Bioconnect Systems Inc-医療機器分野:企業M&A・提携分析
    Summary Bioconnect Systems, Inc. (Bioconnect) is a medical device company that designs, manufactures and distributes surgical and medical products. The company offers optiflow technology, which is used to provide quick joining vessels. Its technology also provides services such as control over the g …
  • Xtant Medical Holdings Inc (XTNT)-製薬・医療分野:企業M&A・提携分析
    Summary Xtant Medical Holdings Inc (Xtant Medical), formerly Bacterin International Holdings, Inc. is a medical device company that develops regenerative medicine products and medical devices. The company’s products include 3Demin, osteosponge, osteosponge SC, osteoselect DBM Putty, OsteoSTX, osteow …
  • Mineral Resources Ltd
    Mineral Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Mineral Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Genuine Parts Company:企業の戦略・SWOT・財務情報
    Genuine Parts Company - Strategy, SWOT and Corporate Finance Report Summary Genuine Parts Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Dongfang Electric Corporation Ltd (1072):電力:M&Aディール及び事業提携情報
    Summary Dongfang Electric Corporation Ltd (DEC), a subsidiary of Dongfang Electric Corporation, is a power equipment and services company. It designs, manufactures and sells power generation equipment, including turbines for hydro, thermal, and nuclear power generation, wind turbine generator sets, …
  • Sumitomo Heavy Industries Ltd (6302)
    Sumitomo Heavy Industries Ltd (6302) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • China Power Clean Energy Development Co Ltd (735):電力:M&Aディール及び事業提携情報
    Summary China Power Clean Energy Development Co Ltd (CPCE) formerly China Power New Energy Development Co Ltd, is an electric utility. It develops, constructs, owns, operates, and manages clean energy power plants. The company produces electricity through natural gas, wind, hydro, and solar sources. …
  • Pension Insurance Corporation plc:企業の戦略・SWOT・財務情報
    Pension Insurance Corporation plc - Strategy, SWOT and Corporate Finance Report Summary Pension Insurance Corporation plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Rizzani De Eccher S.P.A.:企業の戦略・SWOT・財務分析
    Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report Summary Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Solid Biosciences Inc (SLDB):製薬・医療:M&Aディール及び事業提携情報
    Summary Solid Biosciences Inc (Solid Biosciences) is a life science company focused on developing therapies for duchenne muscular dystrophy (DMD). Its pipeline product candidates include SGT-001, a microdystrophin gene therapy administered through adeno-associated virus (AAV) stabilizes dystrophin g …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆